ClinicalTrials.gg
RecruitingNCT06642220ARRCCUpdated Jul 20, 2025

Ablative Radioembolization of Renal Cell Carcinoma Trial

A Phase 2 interventional study of Y-90 Selective Internal Radiation Therapy (SIRT) in Renal Cell Carcinoma (RCC) and Radioembolization, sponsored by Derek W. Cool. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-20.

Sponsored by Derek W. Cool · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 160 studies in Carcinoma, Renal Cell with a site in Canada — 10 open to participants now, 29 under way, 10 of them phase 3. Carcinoma, Renal Cell · Canada.

Planned enrollment
127th of 142
16 · median 128
Started
2025
with 2 others
Phase 2
37 of 160
2 open now
Primary completion
2028-12
later than 23 of 28 live
Registered
154th of 160
by date

Among the 160 studies in Carcinoma, Renal Cell with a site in Canada, this one is the 127th largest by planned enrollment of the 142 interventional ones that give a count, is one of 3 that started in 2025, is one of 37 in phase 2, reaches primary completion later than 23 of the 28 other live ones, and was the 154th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

10 of the 160 studies in Carcinoma, Renal Cell with a site in Canada are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 160 studies in Carcinoma, Renal Cell with a site in Canada, or all of them as a file.
02

Study summary

Renal cell carcinoma (RCC), the most common type of kidney cancer, is typically treated with surgery; however, there is no established therapy for patients who are not surgical candidates and who have tumours greater than 4.0 cm in size. Selective internal radiation therapy (SIRT) or radioembolization using radioactive spheres containing 90-Yttrium (Y-90) is successful at treating large tumours with high doses of radiation within the liver and might be similarly effective for treating larger RCC tumours in patients, particularly those who are not surgical candidates.

This prospective study will enroll 16 participants with RCC who are not candidates for surgery and treat them with Y-90 radioembolization using a high-dose therapy to see if it is an effective cancer therapy. Primary outcome will be RCC treatment response 1 year after the Y-90 radioembolization. Additionally, the safety, tolerability, and impact on kidney function of the therapy will be monitored for all participants. Patients will be followed for a total of 5 years to evaluate long-term outcome in cancer control and safety of the treatment.

Read the detailed description

Renal cell carcinoma (RCC) is the 8th most common cancer in the United States with 81,610 new cases diagnosed each year. 70% of new RCC cases are localized, non-metastatic at initial diagnosis; however, the risk of disease recurrence or progression to metastatic disease is higher for larger tumors and those with higher grade disease. The standard therapy for localized renal cell carcinoma (RCC) is surgery - either partial or radical nephrectomy. However, a substantial proportion of patients with RCC are not good surgical candidates, as the average age at diagnosis is 64-year-old, and obesity, smoking, hypertension and renal disease known risk factors. Currently there are no established standard-of-care therapies for patients who are not eligible for surgery.

Unmet Clinical Need:

There is a need to establish a definitive, minimally-invasive therapy patients for with large, non-metastatic RCC who are not surgical candidates. For non-surgical candidates with small RCC (\< 4 cm or T1a) percutaneous ablation has been established as an effective minimally-invasive curative therapy. However, there is currently no minimally-invasive standard of care therapy for patients with larger localized RCC (> 4 cm) who are not surgical candidates, despite these patients being at higher risk for developing metastatic disease. Percutaneous ablation can be performed in patients with tumors > 4 cm; however, long term outcomes have not been established and those ablations carry higher risks of major bleeding complications than ablation of tumours \< 4 cm. SBRT has shown some promising progression-free survival data for localized RCC; however, the radiation resistance of RCC cells require higher treatment doses to achieve cytotoxic effect. The achievable therapeutic dose of SBRT is currently limited to 30-60 Gy, often due to required reductions in the externally delivered dose to protect the commonly adjacent radiosensitive colon and/or small bowel that routinely abut the kidney.

Selective internal radiation therapy (SIRT) or Yittrium-90 (Y-90) radioembolization is an endovascular therapy whereby beads loaded with the radioactive Yittrium-90 atom are injected through a catheter into the artery or arteries supplying the tumor to deliver the radiation dose internally. Radioactive decay of the Y-90 atom within the tumor's arterial bed, deposits radiation dose within 2.5 mm (maximum 11 mm) of the bead location. As such, the internal delivery of radiation, rather than external delivery of SBRT, allows for higher doses to be delivered to the tumour without exposing adjacent vulnerable organs to significant dose. Y-90 radioembolization has great success treating hepatocellular carcinoma (HCC) in the liver, commonly achieving tumor dose levels that are nearly ten times higher than SBRT (e.g. 300-500 Gy vs. 40-50 Gy). Furthermore, it has become a standard of care therapy for HCC with recent inclusion in the major international treatment guidelines. Y-90 tumor dosage of >400 Gy is the typical target with one major explant study showing complete pathological necrosis of HCC tumors when this dose was achieved8.

RCC is a good potential disease target for Y-90 radioembolization as RCC is commonly hypervascular (similar to HCC) and the kidney is an end organ typically supplied by a single renal artery. Furthermore, the radioresistant tumour biology requires high radiation doses to achieve oncologic effect, which may be best achieved with the internal radiation delivery approach.

Existing Safety Data of Y-90 in the kidney:

Health Canada approval of Y-90 radioembolization is currently only for treatment of malignancies in the liver, where it is currently a standard of care therapy for treatment of HCC. The safety of Y-90 radioembolization in the kidney has been shown in preclinical studies as well as the RESIRT Phase I trial, which is the first and only human clinical trial of Y-90 radioembolization for RCC. The 21-patient RESIRT dose-escalation study had a heterogeneous patient population with both metastatic and non-metastatic RCC. The safety study showed no dose-limiting toxicity or reduction in renal function for treatment between 75-300 Gy; however, the secondary outcome of treatment response showed partial response in only 10% of patients without any complete response. The limited treatment response is potentially related to the administered dose being lower than the 400 Gy target used in the liver for complete pathologic necrosis. For HCC, complete pathologic necrosis from Y-90 SIRT requires an achieved tumour dose of ≥400 Gy. Within the liver, Y-90 administration of tumour doses ranging between 500-1000 Gy have been tolerated without serious adverse events.

Given the known radioresistance of RCC, it is reasonable to expect that a similar or higher dose than HCC would be required to achieve an ablative therapy (i.e. ≥ 400 Gy). The RESIRT trial used resin beads for Y-90 delivery (SIRspheres, Australia) and arterial bed stasis (not permitting additional bead administration) occurred in 52% of the treated patients, which might have limited higher achievable RCC doses. Glass-sphere beads loaded with Y-90 (Therasphere, Boston Scientific) will be used instead of resin, which have higher Y-90 radiation activity per bead than the resin counterparts (2,500 Bq/bead vs. 50 Bq/bead). The higher activity per bead should overcome the maximum dose limitation in the RESIRT trial to achieve the 400+ Gy dose likely required to for complete pathologic necrosis. This is supported by a recent case report where radioembolization with Y-90 loaded on glass spheres achieved complete tumor response after delivering 1,050 Gy into a 1.5 cm RCC without any reported adverse events.

Planned Study:

A single-centre, phase II clinical trial is proposed to evaluate the oncologic efficacy of Y-90 radioembolization treatment within the kidney for patients with large (>4.0 cm), non-metastatic (localized) RCC who are not candidates or refuse the standard of care surgery. It is proposed that Y-90 radioembolization therapy with an ablative dose (400-600 Gy) into RCC within the kidney will achieve positive oncologic response and be tolerated clinically.

03

Conditions studied

  • Renal Cell Carcinoma (RCC)
  • Radioembolization

Keywords

  • renal cell carcinoma
  • radioembolization
  • selective internal radiation therapy (SIRT)
  • Y-90
  • Transarterial radioembolization (TARE)
  • RCC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients willing to participate and provide written consent
  • Patients 18 years of age and older
  • (ECOG) performance status (PS) ≤2
  • confirmed RCC > 4.0 cm and no renal vein or IVC involvement (T1b or T2 disease)
  • Not suitable for or declining standard of care nephrectomy or partial nephrectomy
  • Adequate hepatic function, defined by the following laboratory results:
  • (AST) and alanine aminotransferase (ALT) ≤2.5 × (ULN) (or ≤5 × ULN if presence of liver )
  • Total ≤3 × ULN
  • Serum albumin ≥3.0 g/dL unless (PT) is within the normal range
  • Adequate hematologic function, defined by the following laboratory results:
  • concentration ≥8.0 g/dL
  • (ANC) ≥1000 cells/µL (≥1000 cells/mm3 )
  • >50 × 109 /L (100 × 103 /mm3 )
  • For women of (WOCBP):
  • Negative serum pregnancy test within 48 hours prior to the first dose of study treatment
  • Agreement to use barrier and a second form of highly effective contraception (Clinical Trials Facilitation Group [CTFG] 2020) while receiving study treatment and for 7 months following their last dose of study treatment. Alternatively, total abstinence is also considered a highly effective contraception method when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
  • Sexually active male subjects must use a condom during intercourse while receiving treatment and for at least 120 days after the last dose of the study treatment and should not father a child during this period.
  • Male study subjects whose sexual partners are WOCBP must also agree to use a second form of highly effective contraception (CTFG 2020) while receiving 90Y and for at least 4 months following their last dose. Alternatively, total abstinence is also considered a highly effective contraception method when this is in line with the preferred and usual lifestyle of the subject.
  • Vasectomized men are also required to use a condom during intercourse, including with a male partner, to prevent delivery of the drug via seminal fluid.

Exclusion criteria

Exclusion Criteria:

  • Evidence of disease on CT or MRI
  • Severely impaired renal function ( ≤ 30 mL/min/1.73m²) and not on dialysis
  • Bilateral RCC without plan for definitive therapy of the contralateral lesion
  • RCC that is locally recurrent at prior surgery or ablation site (new location in same or contralateral kidney is permitted)
  • Prior or concurrent kidney radiation therapy or systemic immunotherapy/TKI
  • Lung shunt with estimated lung radiation dose > 30 Gy for single dose or > 50 Gy total.
  • Planning angiogram cone beam CT from all accessible feeding arteries shows lack of perfusion to all or portions of the RCC tumour such that, in the investigator's opinion, Y-90 radioembolization would result in substantial RCC tumour being untreated or receive an inadequate dose.
  • to arterial renal angiogram, or both CT and MRI contrast medium
  • History of severe allergy to CT contrast medium or any study product ingredients that cannot be managed medically
  • History of chronic lung disease with baseline oxygen saturation \< 90% or requiring home oxygen therapy.
  • Congestive heart failure with \< 40%
  • Presence of active infection, defined by the investigator as .
  • Any chronic condition that is severe or unstable and, in the opinion of the investigator, would put the patient at unacceptable risk of adverse event related to the Y-90 radioembolization procedure. Such conditions include but are not limited to: unstable angina, congestive heart failure, interstitial lung disease, severe gastrointestinal disease with diarrhea.
  • > 1 year
  • Pregnant or breast-feeding patient
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Y-90 radioembolization treatment arm

    Patients with non-metastatic renal cell carcinoma (RCC) that is \> 4 cm without local invasion (i.e. T1b or T2) who are poor candidates for surgery will have their tumors treated with transarterial radioembolization with Y-90 glass spheres.

    Device: Y-90 Selective Internal Radiation Therapy (SIRT)

Interventions

  • DeviceY-90 Selective Internal Radiation Therapy (SIRT)

    Y-90 radioembolization will be performed using glass spheres to treat non-metastatic RCC within the kidney.

06

What researchers measure

Primary outcomes

  1. Oncologic tumor response at 12 months

    Assessment the cancer treatment response within the 12 months after treatment. Oncologic response will be based on the modified RECIST (mRECIST) criteria.

    Time frame: From treatment until 12 months follow-up imaging

Secondary outcomes

  1. Treatment-related Adverse Events

    Clinician assessment will occur at 4-weeks, 3-months, 6-months \&amp; 12-months post-treatment and annually to 5 years. All adverse events will be categorized and graded based on Common Terminology Criteria for Adverse Events (CTCAE) grading system. All adverse events will be further classified based on relatedness to either a) the Therapeutic Intervention and b) Y-90 Radiation Dose by the following: a) unrelated, b) unlikely to be related, c) possibly related, d) probably related, e) definitely related. Therapeutic Intervention: Includes all procedure-related adverse events during the planning angiogram or Y-90 therapy procedures (all Y-90 Radiation Dose adverse events included as well). Y-90 Radiation Dose: Subset of Therapeutic Intervention that includes only those adverse events related to the Y-90 radiation therapy. Examples of dose-related events might include post-procedure fatigue/malaise, radiation colitis, acute kidney injury not related to a catheter arterial injury.

    Time frame: Evaluated from Y-90 therapy until 30 days, 1 year &amp; 5 year follow-up

  2. Safety and tolerability of ablative doses (400-600 Gy) of Y-90 spheres administered in the kidney

    Tolerability of the radiation will be characterized by dose-limiting toxicity (DLT) events. The DLT review period will be 30 days after Y-90 procedure. Any serious adverse event that is possibly, probably or definitely related to Y-90 Radiation Dose will be classified as a dose-limiting toxicity (DLT) event. Complications related only to catheter arterial embolization procedure (example puncture site bleeding, artery dissection, etc) or the planning angiogram will not be considered a DLT. Greater \> 1 in 6 patients experiencing DLT events will declare the maximally administered dose and require a reduction in the target dose to 300 Gy. If no DLT events occur during the DLT review period for the first three patients or 1 in the first 6 patients, then the tumour target dose for future participants can be increased up to a maximum of 600 Gy (range 400-600 Gy) at the treating physician's discretion.

    Time frame: Evaluated from Y-90 therapy until 30 days, 1 year &amp; 5 year follow-up

  3. Impact on global renal function

    Assessment of global renal function will be based on the glomerular filtration rate (GFR), calculated using the CKD-EPI Creatinine Equation (2021). GFR will be collected at baseline and at each clinical follow-up post-therapy to assess for change.

    Time frame: Will be evaluated at the time of Y-90 therapy as well as after Y-90 therapy at 3 months (10-16 weeks), 6 months (24-30 weeks), 12 months (50-56 weeks), & 2-, 3-, 4-, 5-years time points

  4. Patient-reported outcomes

    Patient-defined symptomatic adverse events: Self-reported by participants using the National Cancer Institute's Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) form. Overall Side Effect Impact: Measured by the Functional Assessment of Cancer Therapy-GP5 (FACT-GP5) question from the FACT-G questionnaire - "I am bothered by side effects of treatment". Pain intensity measured by 11-point Numerical Pain Rating Score. Health-related quality of life measures: Quality of life and health utility will be self-reported using the EuroQol Group EQ-5D-5L form. This 5-level form evaluates 5 dimensions of (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and can generate a global preference-based score that can be used to estimate quality-adjusted life years (QALY) within the Canadian population context to facilitate cost-utility analysis.

    Time frame: Collected at enrollment and then at 7-days, 14-days, 30-days &amp; 3 months after Y-90 therapy.

  5. Change in Split Renal Function

    Estimation of the split renal function in all participants with two kidneys will be calculated based on established renal parenchymal volume equation calculated from the CT or MR scans. Changes in the split renal function following therapy will be collected at each imaging follow up

    Time frame: Will be calculated at the time of Y-90 therapy (baseline) as well as after Y-90 therapy at 3 months (10-16 weeks), 6 months (24-30 weeks), 12 months (50-56 weeks), & 2-, 3-, 4-, 5-years

  6. Progression free survival out to 5 years

    Progression-free survival will be evaluated based on the modified RECIST (mRECIST) criteria.

    Time frame: Greater than 1 year after Y-90 therapy, up to 5 years post therapy.

  7. Metastasis-free survival out to 5 years

    Metastasis-free survival oncologic response will be calculated.

    Time frame: Greater than 1 year after Y-90 therapy, up to 5 years post therapy

  8. Overall survival out to 5 years

    Overall survival will be calculated.

    Time frame: Greater than 1 year after Y-90 therapy, up to 5 years post therapy

  9. Local Progression free survival out to 5 years

    Local progression-free survival will be evaluated looking only at the response of the treated RCC tumor based on the modified RECIST (mRECIST) criteria. This will be evaluated out to 5 years.

    Time frame: Greater than 1 year after Y-90 therapy, up to 5 years post therapy.

  10. Oncologic Response based on PSMA PET

    Optional Exploratory outcome - Gallium Prostate specific membrane antigen (PSMA) PET-CT be performed at baseline, 3 months and 12 months to assess the impact of Y-90 therapy on the PSMA avidity of RCC tumor. Functional imaging of PSMA PET might provide an earlier assessment of RCC tumour response as compared to the conventional contrast-enhanced CT or MRI assessment.

    Time frame: scans at enrollment, and 3 months and 12 months after Y-90 therapy

  11. Change in renal volume and morphology post-therapy

    Shape-based 3D volumetric assessment of the treated kidney will be evaluated at different time points to identify long-term changes to the kidney volume and contour shape that are potentially treatment related.

    Time frame: From enrollment until 5-years post-therapy

  12. Procedure Time

    The time of the interventional radiology procedure will be recorded. Including a) total room time (time between patient entering and leaving room) and b) total angiogram procedure time (from arterial puncture until final catheter removal) for both the planning angiogram and Y-90 therapy procedures will be recorded.

    Time frame: Will be recorded immediately after the planning angiogram procedure and again after the Y-90 therapy procedure.

  13. Procedure Costs

    All procedure-related costs for the interventional radiology angiogram procedure (in CAD) will be recorded (e.g. Y-90 particles, disposable catheters, wires, total time in interventional radiology suite) for both the planning angiogram and the Y-90 therapy procedures.

    Time frame: Will be recorded immediately after the planning angiogram procedure and again after the Y-90 therapy procedure.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Summerlin AL, Lockhart ME, Strang AM, Kolettis PN, Fineberg NS, Smith JK. Determination of split renal function by 3D reconstruction of CT angiograms: a comparison with gamma camera renography. AJR Am J Roentgenol. 2008 Nov;191(5):1552-8. doi: 10.2214/AJR.07.4023. PubMed 18941100 ↗
  • Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, Amtmann D, Bode R, Buysse D, Choi S, Cook K, Devellis R, DeWalt D, Fries JF, Gershon R, Hahn EA, Lai JS, Pilkonis P, Revicki D, Rose M, Weinfurt K, Hays R; PROMIS Cooperative Group. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol. 2010 Nov;63(11):1179-94. doi: 10.1016/j.jclinepi.2010.04.011. Epub 2010 Aug 4. PubMed 20685078 ↗
  • Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010 Feb;30(1):52-60. doi: 10.1055/s-0030-1247132. Epub 2010 Feb 19. PubMed 20175033 ↗
  • MacKie S, de Silva S, Aslan P, Ladd L, Houang M, Cade D, Delprado W. Super selective radio embolization of the porcine kidney with 90yttrium resin microspheres: a feasibility, safety and dose ranging study. J Urol. 2011 Jan;185(1):285-90. doi: 10.1016/j.juro.2010.09.001. PubMed 21075399 ↗
  • de Silva S, Mackie S, Aslan P, Cade D, Delprado W. Histological Comparison of Kidney Tissue Following Radioembolization with Yttrium-90 Resin Microspheres and Embolization with Bland Microspheres. Cardiovasc Intervent Radiol. 2016 Dec;39(12):1743-1749. doi: 10.1007/s00270-016-1482-3. Epub 2016 Oct 14. PubMed 27743088 ↗
  • Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19. PubMed 34801630 ↗
  • Tong AK, Kao YH, Too CW, Chin KF, Ng DC, Chow PK. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. Br J Radiol. 2016 Jun;89(1062):20150943. doi: 10.1259/bjr.20150943. Epub 2016 Mar 24. PubMed 26943239 ↗
  • Gabr A, Kulik L, Mouli S, Riaz A, Ali R, Desai K, Mora RA, Ganger D, Maddur H, Flamm S, Boike J, Moore C, Thornburg B, Alasadi A, Baker T, Borja-Cacho D, Katariya N, Ladner DP, Caicedo JC, Lewandowski RJ, Salem R. Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort. Hepatology. 2021 Mar;73(3):998-1010. doi: 10.1002/hep.31318. Epub 2020 Nov 7. PubMed 32416631 ↗
  • Kluetz PG, Slagle A, Papadopoulos EJ, Johnson LL, Donoghue M, Kwitkowski VE, Chen WH, Sridhara R, Farrell AT, Keegan P, Kim G, Pazdur R. Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms. Clin Cancer Res. 2016 Apr 1;22(7):1553-8. doi: 10.1158/1078-0432.CCR-15-2035. Epub 2016 Jan 12. PubMed 26758559 ↗
  • McGregor H, Laidlaw G, Johnson G. Ablative Radioembolization of a Synchronous Renal Cell Carcinoma and Hepatocellular Carcinoma. J Vasc Interv Radiol. 2023 Oct;34(10):1847-1849. doi: 10.1016/j.jvir.2023.06.028. Epub 2023 Jun 28. No abstract available. PubMed 37391075 ↗
  • Hamoui N, Gates VL, Gonzalez J, Lewandowski RJ, Salem R. Radioembolization of renal cell carcinoma using yttrium-90 microspheres. J Vasc Interv Radiol. 2013 Feb;24(2):298-300. doi: 10.1016/j.jvir.2012.10.027. Epub 2013 Jan 28. No abstract available. PubMed 23369565 ↗
  • de Souza PL, Aslan P, Clark W, Nour R, de Silva S. RESIRT: A Phase 1 Study of Selective Internal Radiation Therapy Using Yttrium-90 Resin Microspheres in Patients With Primary Renal Cell Carcinoma. Clin Genitourin Cancer. 2022 Oct;20(5):442-451. doi: 10.1016/j.clgc.2022.05.006. Epub 2022 May 18. PubMed 35710899 ↗

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

Time frame: Beginning 3 months after publication and ending 48 months after article publication.

Access criteria: Researchers who provide a methodologically sound proposal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2028, 41 months after the start.

Of 185 non-industry phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 98. This study's planned 41 months is below that.

Counting every sponsor, half of 232 studies reached it within 58 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2024
First posted
Oct 15, 2024
StartActual
Jul 9, 2025
Primary completionEst.
Dec 2028
CompletionEst.
Dec 31, 2032
Last update
Jul 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06642220
Lead sponsor
Derek W. Cool
Responsible party
Derek W. Cool (Principal Investigator, Western University, Canada) — Sponsor-investigator
First posted
Oct 15, 2024
Start date
Jul 9, 2025
Primary completion
Dec 2028 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Jul 20, 2025

Study contacts

Sarah DeBrabandere, PhD
Contact
sarah.debrabandere@lhsc.on.ca
5196858500
Craig Johnson, PhD
Contact
craig.johnson@lhsc.on.ca

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion